Related Experiment Videos
Drug interactions with irbesartan.
1Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 18543, USA.
Clinical Pharmacokinetics
|August 29, 2001
Summary
Irbesartan, an angiotensin II receptor antagonist, shows minimal drug and food interactions. Clinical trials indicate it is safe for long-term hypertension management with common medications and foods.
Area of Science:
- Pharmacology
- Drug Metabolism
- Clinical Pharmacy
Background:
- Irbesartan is an angiotensin II receptor antagonist for hypertension.
- Hypertension management often requires long-term treatment and concurrent medications.
- Understanding drug and food interactions is crucial for patient safety.
Purpose of the Study:
- To review drug and food interaction trials involving irbesartan.
- To assess the clinical significance of potential interactions.
- To inform safe prescribing practices for irbesartan.
Main Methods:
- Literature review of conducted drug and food interaction trials.
- Analysis of pharmacokinetic data from interaction studies.
- Evaluation of potential clinical significance of observed changes.
Main Results:
- No significant interactions were identified between irbesartan and common co-administered drugs (e.g., hydrochlorothiazide, nifedipine, warfarin) or food.
- Fluconazole increased irbesartan plasma concentrations, but the effect was deemed not clinically significant.
- Irbesartan undergoes metabolism primarily via CYP2C9 and minimally via CYP3A4.
Conclusions:
- Irbesartan exhibits a low potential for clinically significant drug and food interactions.
- This favorable interaction profile supports its use in patients requiring concurrent medications for hypertension.
- Further research may explore interactions with a broader range of agents.